---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-271965"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2024-12-06T23:59:59+00:00"
generated_at: "2026-05-29T06:39:36.307411+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics appoints Sravan Emany as CFO effective Dec 19, 2024

## Summary
- Sravan Emany previously CFO/COO of Ironwood Pharmaceuticals; also held roles at Integra, Bank of America, Goldman Sachs.
- Annual base salary of $575,000; sign-on bonus of $325,000; target annual incentive bonus of 50% of salary.
- Granted incentive stock option for 160,000 shares and restricted stock units for 80,000 shares, both vesting over four years.
- Under the offer letter, severance includes 12 months base salary and COBRA premiums if terminated without cause.
- Appointment effective December 19, 2024; Emany will serve as principal financial officer.

## SEC filing metadata
- accession: 0001193125-24-271965
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2024-12-06T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312524271965/0001193125-24-271965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312524271965/d888673d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-271965
- JSON: https://secwatch.observer/filing/0001193125-24-271965.json
- Plain text: https://secwatch.observer/filing/0001193125-24-271965.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.